Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04499248 · ClinicalTrials.gov registry record · Phase 1
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
A Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT04499248 is a Phase 1 study of Ocular Hypertension and Open Angle Glaucoma that is actively recruiting participants, run by AbbVie. The registered enrollment target is 96 participants, below the 276-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04499248, a Phase 1 study of Ocular Hypertension and Open Angle Glaucoma, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Conditions Studied
Interventions
- DRUG AGN-193408 SR
- OTHER Lumigan
- OTHER Sham Administration
- OTHER Lumigan Vehicle
Study Locations (20)
California
- Global Research Management /ID# 241699 - Glendale
- United Medical Research Institute /ID# 241701 - Inglewood
- Lakeside Vision Center /ID# 241698 - Irvine
- The Eye Research Foundation /ID# 234528 - Newport Beach
- Sacramento Eye Consultants /ID# 241697 - Sacramento
- Premiere Practice Management LLC /ID# 235957 - Torrance
- Wolstan & Goldberg Eye Associates /ID# 241700 - Torrance
Florida
- Brandon Eye Associates - Brandon /ID# 276600 - Brandon
- Nature Coast Clinical Research - Crystal River /ID# 237781 - Crystal River
- Advanced Research, LLC /ID# 276987 - Deerfield Beach
- University of Florida Health Ophthalmology - Jacksonville /ID# 243122 - Jacksonville
- East Florida Eye Institute /ID# 235762 - Stuart
- Logan Ophthalmic Research Inc. /ID# 252087 - Tamarac
Georgia
- Coastal Research Associates /ID# 234649 - Roswell
- Thomas Eye Group PC /ID# 266775 - Sandy Springs
Indiana
- Midwest Medical Advisors Inc /ID# 235845 - Carmel
- Indiana University - Glick Eye Institute /ID# 235887 - Indianapolis
Arizona
- Horizon Eye Specialists & Lasik Center - Sun City /ID# 252153 - Sun City
Connecticut
- Connecticut Eye Consultants P.C. /ID# 235862 - Danbury
Illinois
- University of Illinois Hospital and Health Sciences System /ID# 253630 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04499248
The ClinicalTrials.gov registry entry for NCT04499248 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (65% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 4 interventions - of which AGN-193408 SR is the first listed.
NCT04499248 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04499248 about?
NCT04499248 is a clinical study titled "AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension". This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
What is the current status of trial NCT04499248?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2020-11-16. Estimated completion is 2029-02.
What conditions does trial NCT04499248 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT04499248?
The interventions under investigation include: AGN-193408 SR (DRUG), Lumigan (OTHER), Sham Administration (OTHER), Lumigan Vehicle (OTHER).
Who is sponsoring clinical trial NCT04499248?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04499248 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
COMPLETED · Phase 1
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.